BlackRock’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,612
| Closed | -$1.01K | – | 5627 |
|
|
2023
Q2 | $1.01K | Hold |
4,612
| – | – | ﹤0.01% | 5406 |
|
|
2023
Q1 | $1.45K | Sell |
4,612
-12,651
| -73% | -$9.19K | ﹤0.01% | 5453 |
|
|
2022
Q4 | $20.4K | Sell |
17,263
-185
| -1% | -$179 | ﹤0.01% | 5376 |
|
|
2022
Q3 | $16K | Sell |
17,448
-287
| -2% | -$446 | ﹤0.01% | 5548 |
|
|
2022
Q2 | $20K | Sell |
17,735
-18,091
| -50% | -$22.5K | ﹤0.01% | 5559 |
|
|
2022
Q1 | $63K | Sell |
35,826
-7,375
| -17% | -$14K | ﹤0.01% | 5381 |
|
|
2021
Q4 | $101K | Buy |
43,201
+974
| +2% | +$2.77K | ﹤0.01% | 5271 |
|
|
2021
Q3 | $156K | Buy |
42,227
+10,614
| +34% | +$49K | ﹤0.01% | 5038 |
|
|
2021
Q2 | $234K | Buy |
31,613
+5,232
| +20% | +$32.7K | ﹤0.01% | 4872 |
|
|
2021
Q1 | $156K | Buy |
26,381
+2,702
| +11% | +$18.3K | ﹤0.01% | 4778 |
|
|
2020
Q4 | $144K | Buy |
23,679
+1,079
| +5% | +$7.54K | ﹤0.01% | 4526 |
|
|
2020
Q3 | $160K | Buy |
22,600
+2,972
| +15% | +$20.7K | ﹤0.01% | 4442 |
|
|
2020
Q2 | $131K | Buy |
19,628
+13,343
| +212% | +$92.1K | ﹤0.01% | 4445 |
|
|
2020
Q1 | $36K | Buy |
6,285
+570
| +10% | +$3.63K | ﹤0.01% | 4531 |
|
|
2019
Q4 | $25K | Buy |
5,715
+4,493
| +368% | +$23.7K | ﹤0.01% | 4629 |
|
|
2019
Q3 | $8K | Hold |
1,222
| – | – | ﹤0.01% | 4742 |
|
|
2019
Q2 | $12K | Buy |
+1,222
| New | +$11.8K | ﹤0.01% | 4752 |
|
Other funds holding ARDS
BlackRock's ARDS Position: Q3 2023 in Review
BlackRock sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 4,612 shares — an estimated $1.01K sold.
BlackRock first reported a position in ARDS in Q2 2019 and held it in 17 quarters. The position peaked at $234K in Q2 2021. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.
- BlackRock reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- BlackRock sold 4,612 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $1.01K.
- BlackRock first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q2 2019 and held it in 17 quarters.
- BlackRock's Aridis Pharmaceuticals Inc. Common Stock position peaked at $234K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.
Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.